PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The study will be conducted at up to 25 U.S. centers and will be a double-blind randomized
parallel group placebo controlled study among subjects with stable coronary artery disease
(CAD). Subjects will be randomized to receive either placebo tablets or one of 2 orally
active doses of A-002. The duration of study drug therapy will be 8 weeks.